SLVRGEN® is a novel synergistic formulation consisting of recombinant human Epidermal Growth Factor (rhEGF) with Silver Sulfadiazine (SSD) and Chlorhexidine Gluconate (CHG). It is a topical gel used for faster healing of first- and second-degree burns.

SLVRGEN® is stable at room temperature 250C. Keep SLVRGEN® out of the reach and sight of children.

SLVRGEN® should not be applied if

  • You are allergic to any of its components
  • You are pregnant woman or a nursing mother
  • You are an immunocompromised individual
  • You are receiving immunosuppressive or immunostimulant medications.

The burn wounds should be cleaned and SLVRGEN® cream should be applied over all the affected areas to a depth of 3 to 5 mm. One technique is to apply the cream with a sterile gloved hand and/or sterile spatula. Where necessary, the cream should be re-applied to the area from which it has been removed by patient activity. SLVRGEN® should be applied at least every 24 hours.

SLVRGEN® is developed using Recombinant Human Epidermal Growth Factor (rhEGF),involved in mechanisms such as normal cell growth & wound healing. Silver Sulfadiazine acts as antimicrobial and exhibits bactericidal property & is effective against yeast. Chlorhexidine Gluconate has antiseptic & antibacterial effects. It alters protein structure and configuration.

The conventional SSD usage delays wound healing process by absorption of silver from burn wounds leading to cytotoxicity and bacterial resistance. The cytotoxic property of SSD in retarding the wound healing can be reversed with the addition of rhEGF. SLVRGEN® synergistically plays a vital role in controlling infection & also promoting fast wound healing.

SLVRGEN® is cost effective in comparison with other commercially available topical gels as it significantly decreases the time of burn wound closure, follow-up visits & number of tubes required.